Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.
Claude FlamandChristelle Alves SarmentoAntoine EnfissiSarah BaillyEmmanuel BeillardMélanie GailletCéline MichaudVéronique ServasNathalie ClementAnaïs PerilhouThierry CarageDidier MussoJean-François CarodStéphanie EustacheCéline TourbillonElodie BoizonSamantha JamesFélix DjossouHenrik SaljeSimon CauchemezDominique RoussetPublished in: PLoS neglected tropical diseases (2021)
The overall seroprevalence was 15.4% [9.3%-24.4%] among 480 participants, ranging from 4.0% to 25.5% across the different municipalities. The seroprevalence did not differ according to gender (p = 0.19) or age (p = 0.51). Among SARS-CoV-2 positive individuals, we found that 24.6% [11.5%-45.2%] reported symptoms consistent with COVID-19. Our findings revealed high levels of infection across the territory but a low number of resulting deaths, which can be explained by French Guiana's young population structure.